



FINANCIAL TEAR SHEET

Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

Primary IR Contact

Andre'a Lucca
 Director of Communications
 PlasmaTech
 Biopharmaceuticals, Inc.
Phone: 212-786-6208
E-mail:
 alucca@plasmatechbio.com

Stock Performance

ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$7.37
Change (%)	▼ 0.22 (2.77%)
Volume	516,869
52 Week Low	\$6.94
Market Cap	\$353,111,139
Rolling EPS	-0.96
PE Ratio	0
Shares Outstanding	47,944,486



Data as of December 14, 2018 4:00 p.m. ET

Recent Press Releases & Upcoming Events

December 6, 2018
Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day

November 29, 2018
Abeona Therapeutics to Host R&D Day on December 6, 2018

November 26, 2018
Abeona Therapeutics Announces CEO Transition

There are currently no events scheduled.

SEC Filings

Filing Date	Form
December 6, 2018	8-K
November 30, 2018	8-K
November 9, 2018	8-K
November 9, 2018	10-Q

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.